AstraZeneca's Dato-DXd trial in metastatic breast cancer showed progression-free survival improvement but not overall survival.
AstraZeneca's phase three trial for datopotamab deruxtecan (Dato-DXd) in metastatic hormone receptor-positive, HER2-low or negative breast cancer did not show significant overall survival improvement compared to chemotherapy, although it met its primary endpoint of progression-free survival. The company will discuss the findings with regulators. Additionally, AstraZeneca's Fasenra received a positive EU recommendation for treating eosinophilic granulomatosis with polyangiitis.
September 23, 2024
17 Articles